IPO - Hinge Health, Inc.

Form Type: 424B4

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: New

Accession Number: 000119312525125262

Filing Summary: Hinge Health, Inc. is conducting an initial public offering (IPO) of 13,666,000 shares of Class A common stock, with 8,522,528 shares being offered by the company and 5,143,472 shares offered by selling stockholders. The initial public offering price is set at $32.00 per share, and the company has obtained approval to list the shares on the New York Stock Exchange under the ticker symbol 'HNGE'. This IPO marks Hinge Health's entry into the public market, as no prior market for its shares exists. Proceeds from this offering will not be received by Hinge Health from the selling stockholders' shares. After the IPO, the company will have two classes of stock: Class A and Class B, with Class A shareholders receiving one vote per share and Class B shareholders receiving 15 votes per share. Approximately 97.1% of the voting power will reside with the holders of the Class B shares, including directors and executive officers. The underwriters will have a 30-day option to purchase an additional 2,049,900 shares. The IPO aims to raise significant capital for the company, which focuses on transforming musculoskeletal care through technological innovations. Risk factors pertaining to the investment are discussed in the document, and a wide range of financial metrics and performance details are provided, showcasing the company's growth and operational efficiencies.

Form Type: 8-K

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: New

Accession Number: 000119312525125916

Filing Summary: On May 23, 2025, Hinge Health, Inc. filed its amended and restated certificate of incorporation and bylaws, effective in connection with the closing of its initial public offering (IPO) of shares of Class A common stock. The IPO resulted in the sale of 15,715,900 shares, including 8,522,528 shares sold by the Company and 7,193,372 by selling stockholders, at a public price of $32.00 per share. The total gross proceeds to the Company were approximately $272.7 million. Notably, the Company did not receive proceeds from shares sold by selling stockholders. The amendments were approved by the Company's board and stockholders to take effect immediately before the IPO closing, as detailed in the final prospectus dated May 21, 2025.

Form Type: 8-A12B

Filing Date: 2025-05-19

Corporate Action: Ipo

Type: New

Accession Number: 000119312525122333

Filing Summary: Hinge Health, Inc. has filed Form 8-A for the registration of its Class A Common Stock, valued at $0.00001 per share, under Section 12(b) of the Securities Exchange Act of 1934. The company is incorporated in Delaware with an Employer Identification Number (EIN) of 81-1884841. The shares are intended to be listed on the New York Stock Exchange. The filing incorporates by reference details from its Registration Statement on Form S-1 (File No. 333-285682), originally filed on March 10, 2025, and subsequently amended. Item 2 notes that no exhibits are required for this registration as no other securities of the company are registered on the NYSE and its securities are not being filed under Section 12(g). Daniel Perez, the Chief Executive Officer, authorized this registration on May 19, 2025.

Form Type: S-1/A

Filing Date: 2025-05-16

Corporate Action: Ipo

Type: New

Accession Number: 000119312525121827

Filing Summary: Hinge Health, Inc. is conducting its initial public offering (IPO) by offering 8,522,528 shares of Class A common stock alongside an aggregate offering of 5,143,472 shares by selling stockholders. The anticipated price per share is between $28.00 and $32.00, with no existing public market for these shares at this time. Post-IPO, Hinge Health will have two classes of common stock, Class A with one vote per share and Class B with 15 votes per share. The registration statement also details the company's revenue growth and operational metrics, emphasizing a net dollar retention rate of 117% and a strong client satisfaction score of 87. Hinge Health's platform automates care delivery for musculoskeletal (MSK) conditions, significantly reducing traditional therapy hours by 95% and supporting over one million members to date. Their revenue for 2024 stood at $390 million, reflecting a year-over-year growth rate of 33%. The document highlights various competitive advantages, including technology integration to enhance user experience and a strategic relationship with major healthcare payers to facilitate market entry and client access.

Form Type: S-1/A

Filing Date: 2025-05-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525118259

Filing Summary: Hinge Health, Inc. is conducting its initial public offering (IPO) with the registration of 13,666,000 shares of Class A common stock. Out of these, 8,522,528 shares are being offered by the company and 5,143,472 shares by selling stockholders. The anticipated initial public offering price per share is between $28.00 and $32.00. The offering aims to list the Class A common stock on the New York Stock Exchange under the symbol 'HNGE'. Hinge Health is categorized as an 'emerging growth company' and is primarily focused on transforming musculoskeletal care by leveraging technology to scale and automate care delivery. The company's innovative approach aims to improve patient outcomes and reduce healthcare costs while providing a seamless and personalized member experience. Key metrics indicate substantial growth, with $390 million in revenue for 2024, representing a 33% year-over-year increase. The company has established significant partnerships with major national health plans and boasts high client retention rates, underscoring its potential in the market.

Form Type: S-1/A

Filing Date: 2025-05-05

Corporate Action: Ipo

Type: New

Accession Number: 000119312525112887

Filing Summary: Hinge Health, Inc. is filing an amendment to its registration statement in connection with its initial public offering (IPO) of Class A common stock. The offering involves shares being sold by the company and selling stockholders, with proceeds from the latter not going to Hinge Health. This IPO aims to offer the public their Class A common stock on the New York Stock Exchange under the symbol 'HNGE'. The document outlines the expected price range for the shares, which is yet to be specified, and indicates that the net proceeds from the offering are anticipated to support the company's operations and growth strategies. Hinge Health's platform leverages technology to automate the delivery of musculoskeletal care, utilizing AI, wearable devices, and a comprehensive care team to enhance patient outcomes and patient satisfaction while reducing costs. The firm is categorized as an emerging growth company and highlights the significant revenue growth and high client retention rate they have achieved leading up to this offering.

Form Type: S-1

Filing Date: 2025-03-10

Corporate Action: Ipo

Type: New

Accession Number: 000119312525051004

Filing Summary: Hinge Health, Inc. is filing a registration statement for its initial public offering (IPO) of Class A common stock as per the Securities Act of 1933. The company is offering shares of Class A common stock, though it will not receive any proceeds from the selling stockholders. The anticipated IPO price is expected to range between $____ and $____. Hinge Health currently has no public market for its Class A common stock and has applied to list on the New York Stock Exchange under the symbol 'HNGE'. The offering features two series of common stock, Class A and Class B, with differing voting rights. Class A shares have one vote per share, while Class B shares have 15 votes and can be converted into Class A shares. The company reported significant growth and metrics, with approximately $390 million in revenue in 2024, reflecting a year-over-year growth of 33%. Their services target musculoskeletal (MSK) health care, emphasizing a tech-driven approach that promotes accessibility and improved care outcomes. The filing notes Hinge Health's position as an emerging growth company and outlines its market strategy and financial performance, including a focus on digital and automated healthcare solutions. The document includes key features of the IPO, including underwriters and related conditions.

Form Type: DRS/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000095012325002139

Filing Summary: Hinge Health, Inc. is conducting its initial public offering (IPO) of shares of Class A common stock. The company aims to sell an aggregate of shares while no public market currently exists for its Class A common stock. The estimated initial public offering price is expected to be between a specified range, and the company is seeking to list its stock on the New York Stock Exchange under the symbol 'HH'. Hinge Health's platform leverages technology, including AI, to automate care for joint and muscle health, intending to improve health outcomes, member experiences, and reduce costs. The company has achieved notable growth, reporting significant increases in both clients and member enrollments over the last year. It operates on a recurring revenue model and has retained a high client satisfaction level. Despite the absence of complete financial specifics in this preliminary prospectus, Hinge Health addresses widespread musculoskeletal (MSK) health issues that have a massive impact on healthcare costs and quality of life.

Form Type: DRS/A

Filing Date: 2025-01-17

Corporate Action: Ipo

Type: New

Accession Number: 000095012325000383

Filing Summary: Hinge Health, Inc. is filing a Form DRS/A for its initial public offering (IPO) of Class A common stock. The registration statement was submitted confidentially to the SEC, and it outlines the offering of shares, expected pricing range, and key details of the common stock structure. The company plans to list its Class A common stock under the symbol 'HH'. The IPO aims to raise capital to enhance its automated musculoskeletal (MSK) care platform, which utilizes AI technology and a proprietary wearable device for delivering healthcare solutions. The offering is expected to commence as soon as practicable after the registration statement is effective, with all relevant risks and financial information set to be disclosed in future amendments to the prospectus. As an emerging growth company, Hinge Health may utilize certain reduced reporting requirements.

Form Type: DRS

Filing Date: 2024-11-15

Corporate Action: Ipo

Type: New

Accession Number: 000095012324011929

Filing Summary: Hinge Health, Inc. is preparing for its initial public offering of Class A common stock. The prospectus outlines the company's efforts in transforming musculoskeletal (MSK) care through technology. The platform combines AI, wearable devices, and a team of healthcare professionals to enhance the treatment and prevention of joint and muscle pain, targeting improvements in user experience and cost-efficiency. The company emphasizes a personalized approach to care, providing access to a diverse spectrum of MSK treatments, designed for ease of use and accessibility. Hinge Health has achieved notable milestones, including over one million treated members and substantial activity metrics, reflecting demand and engagement with its services. The anticipated IPO will allow selling stockholders to offer shares alongside the company, although Hinge Health will not receive proceeds from these sales. The offering's initial price range is yet to be determined. Hinge Health positions itself for significant growth within a large telehealth market, addressing gaps in traditional MSK care effectiveness. As part of its growth strategy, the company will continue to work closely with health plans and employers to deliver efficient care solutions. This prospectus outlines the key factors that potential investors should consider, including risks associated with the offering and financial performance projections.